| pubmed-article:7448824 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C1519429 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:7448824 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:7448824 | pubmed:issue | 8-9 | lld:pubmed |
| pubmed-article:7448824 | pubmed:dateCreated | 1981-3-24 | lld:pubmed |
| pubmed-article:7448824 | pubmed:abstractText | The Southwest Oncology Group did a limited institutional pilot study of the combination of doxorubicin and ifosfamide in the treatment of previously treated adult patients with acute leukemia. Thirty-four patients received one or two courses of the combination. All patients had received prior chemotherapy and 32 had received prior anthracycline chemotherapy. Three patients died before their responses could be fully evaluated. Fourteen patients achieved complete remission (41%) and one patient achieved partial remission. The complete remission rate was 27% for patients with acute myeloblastic leukemia (myelomonoblastic leukemia, monoblastic leukemia, and erythroleukemia) and 89% for patients with acute lymphocytic and undifferentiated leukemia (ALL). Toxic effects included severe hematologic reactions in 33 of 34 patients, hematuria in six patients, altered sensorium in one patient, and congestive heart failure in one patient. The safety of the combination was established and toxic side effects of this therapy were tolerable. The 89% complete remission rate for previously treated patients with ALL suggests that the combination of doxorubicin and ifosfamide may be particularly effective in ALL. | lld:pubmed |
| pubmed-article:7448824 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7448824 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7448824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7448824 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7448824 | pubmed:issn | 0361-5960 | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:WilsonH EHE | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:StuckeyW JWJ | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:BottomleyRR | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:HewlettJ SJS | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:RyanD HDH | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:BickersJ NJN | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:VialR HRH | lld:pubmed |
| pubmed-article:7448824 | pubmed:author | pubmed-author:HusseinKK | lld:pubmed |
| pubmed-article:7448824 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7448824 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:7448824 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7448824 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7448824 | pubmed:pagination | 869-72 | lld:pubmed |
| pubmed-article:7448824 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:meshHeading | pubmed-meshheading:7448824-... | lld:pubmed |
| pubmed-article:7448824 | pubmed:articleTitle | Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study. | lld:pubmed |
| pubmed-article:7448824 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7448824 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7448824 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
